US 2787577A
· Allisbaugh
· 1957
[cited by applicant]
US 4683195A
· Mullis
· 1987
[cited by applicant]
US 4683202A
· Mullis
· 1987
[cited by applicant]
US 4754065A
· Levenson
· 1988
[cited by applicant]
US 4800159A
· Mullis
· 1989
[cited by applicant]
US 6723325B1
· Weltzin
· 2004
[cited by applicant]
US 8795667B2
· Johnson
· 2014
[cited by examiner]
US 20040014034A1
· Evans
· 2004
[cited by applicant]
US 20210236619A1
· Lederman
· 2021
[cited by applicant]
CN 105121635A
· 2015
[cited by applicant]
EP 3045181
· 2016
[cited by applicant]
WO WO2005028634
· 2005
[cited by applicant]
WO 2006022215A1
· 2006
[cited by applicant]
WO WO2007093133
· 2007
[cited by applicant]
WO WO2013038066
· 2013
[cited by applicant]
WO WO2014160475
· 2014
[cited by applicant]
WO WO2017027757
· 2017
[cited by applicant]
WO WO2018057755
· 2018
[cited by applicant]
WO WO2018085582
· 2018
[cited by applicant]
WO WO2019043282
· 2019
[cited by applicant]
WO WO2019213452
· 2019
[cited by applicant]
Willer Do, McFadden G, Evans DH. The complete genome sequence of shope (rabbit) fibroma virus. Virology. Nov. 25, 1999;264(2):319-43. Abstract Only. (Year: 1999).
[cited by examiner]
Aragon et al., “Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968,” BMC Public Health 3:26 1-12 (2003).
[cited by applicant]
Aragon et al., “The risks and benefits of pre-event smallpox vaccination: where you stand depends on where you sit,” Annals of Emergency Medicine, 42(5):681-684 (2003).
[cited by applicant]
Artenstein et al., “A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults,” Vaccine, 23: 3301-3309 (2005).
[cited by applicant]
Attwood, “Genomics. The Babel of bioinformatics,” Science, 290(5491):471-473 (2000).
[cited by applicant]
Baker et al., “Protein structure prediction and structural genomics,” Science, 294(5540):93-96 (2001).
[cited by applicant]
Baroudy et al., “Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain,” Cell, 28(2):315-24 (1982).
[cited by applicant]
Baxby, “The origins of vaccinia virus,” Journal of Infectious Disease, 136(3):453-455 (1977).
[cited by applicant]
Brickmann et al., “Re-assembly of nineteenth-century smallpox vaccine genomes reveals the contemporaneous use of horsepox and horsepox-related viruses in the USA,” Genome Biology, 21:286 (2020) (6 pages).
[cited by applicant]
Buller et al., “Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype,” Nature, 317:813-815 (1985).
[cited by applicant]
Chakrabarti et al., “Compact, synthetic, vaccinia virus early/late promoter for protein expression,” BioTechniques, 23(6):1094-1097 (1997).
[cited by applicant]
Child et al., “Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence in vivo,” Virology, 174:625-629 (1990).
[cited by applicant]
Coukos et al., “Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer,” Clinical Cancer Research, 5(6):1523-37 (1999).
[cited by applicant]
Czub et al., “Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets,” Vaccine, 23(17-18):2273-2279 (2005).
[cited by applicant]
Damaso, “Revisiting Jenner's mysteries, the role of the Beaugency lymph in the evolutionary path of ancient smallpox vaccines,” Lancet, S1473-3099(17):30445 (2017) (9 pages).
[cited by applicant]
Di Pilato et al., “Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression,” Journal of General Virology, 96(8):2360-2371 (2015).
[cited by applicant]
Dieuliis et al., “A Holistic Assessment of the Risks and Benefits of the Synthesis of Horsepox Virus,” mSphere, 3(2)e00074-18 (2018) (8 pages).
[cited by applicant]
Du et al., “Vaccinia virus DNA replication: two hundred base pairs of telomeric sequence confer optimal replication efficiency on minichromosome templates,” PNAS, 93(1):9693-9698 (1996).
[cited by applicant]
Earl et al., “Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus,” Journal of …
[cited by applicant]
Esparza et al., “Investigations on the historical origin and evolution of the smallpox vaccine, ” Gac Med Caracas, 128(Supl 1):S88-S97 (2020).
[cited by applicant]
Falkner et al., “
[cited by applicant]
FDA Briefing Document, “Vaccines and Related Biological Products Advisory Committee Meeting,” Sep. 19, 2012 (30 pages).
[cited by applicant]
Frey et al. “Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults,” Vaccine 27:1637-1644 (2009).
[cited by applicant]
Frey et al., “Clinical responses to undiluted and diluted smallpox vaccine,” New England Journal of Medicine, 346:1265-1274 (2002).
[cited by applicant]
Gammon et al., “Vaccinia Virus—Encoded Ribonucleotide Reductase Subunits Are Differentially Required for Replication and Pathogenesis,” Plos Pathogens, 6(7):e1000984, pp. 1-20, 2010.
[cited by applicant]
Garcel et al. “Phenotypic and genetic diversity of the traditional Lister smallpox vaccine,” Vaccine, 27:708-17 (2009).
[cited by applicant]
Garcia-Castro et al., “Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study,” Cancer Gene Therapy, 17(7): 476-83 (2010).
[cited by applicant]
GenBank Accession No. AY313847.1, “Vaccinia virus strain Acambis clone 2000, complete genome” (2010) (82 pages).
[cited by applicant]
Gomez et al., “The Poxvirus Vectors MVA and NYVAC as Gene Delivery Systems for Vaccination Against Infectious Diseases and Cancer,” Current Gene Therapy, 8(2):97-120 (2008).
[cited by applicant]
Greenberg et al., “ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine,” Expert Opinion on Investigational Drugs, 17:555-564 (2008).
[cited by applicant]
Hartman et al., “SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts,” PLOS …
[cited by applicant]
Hendrickson et al., “Orthopoxvirus genome evolution: the role of gene loss,” Viruses, 2:1933-1967 (2010).
[cited by applicant]
Himly et al., “The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses,” Virology, 248(2):295-304 (1998).
[cited by applicant]
Imperiale, “Re-creation of Horsepox Virus,” mSphere, 3(2)e00079-18 (2018) (1 page).
[cited by applicant]
Jefferson et al., “The mechanisms of genetically modified vaccinia viruses for the treatment of cancer,” Critical Reviews in Oncology/Hematology, 95(3):407-416 (2015).
[cited by applicant]
Jenner, “An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of The Cow Pox,” Springfield…
[cited by applicant]
Kennedy et al., “T-Cell epitope discovery for variola and vaccinia viruses,” Reviews in Medical Virology,17: 93-113 (2007).
[cited by applicant]
Koblentz, “A Critical Analysis of the Scientific and Commercial Rationales for the De Novo Synthesis of Horsepox Virus,” mSphere, 3(2)e00040-18 (2018) (10 pages).
[cited by applicant]
Koblentz, “The De Novo Synthesis of Horsepox Virus: Implications for Biosecurity and Recommendations for Preventing the Reemergence of Smallpox,” Health Security, 15(5):620-628 (2017).
[cited by applicant]
Kolb et al., “Improvements in the rabbit scarification method for the assay of smallpox vaccine,” Bulletin of the World Health Organization, 25(1):19-24 (1961).
[cited by applicant]
Korber et al., “Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,” bioRxiv 2020.04.29.069054 (2020) (33 pages).
[cited by applicant]
Kremer et al., “Vaccinia virus and poxvirology, Methods and Protocols,” Second Edition, vol. 890, Humana Press, Totowa, NJ pp. 59-92 (2012) (339 pages).
[cited by applicant]
Kupferschmidt, “A paper showing how to make a smallpox cousin just got published. Critics wonder why,” downloaded from http://www.sciencemag.org/news/2018/01/paper-showing-how-make-smallpox-cousin-just-got-published-cri…
[cited by applicant]
Kupferschmidt, “How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA,” Science Magazine (2017) (5 pages).
[cited by applicant]
Kushner, “Synthetic Biology Could Bring a Pox on US All,” Science, (18 pages) (2019).
[cited by applicant]
Leon et al., “The EB66® cell line as a valuable cell substrate for MVA-based vaccines production,” Vaccine, 34(48):5878-5885 (2016).
[cited by applicant]
Li et al., Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication, Virology Journal, 3:88; 9 pages (2006).
[cited by applicant]
Li et al., “Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A,” Journal of General Virology, 94(Pt. 4):806-815 (2014).
[cited by applicant]
Li et al., “On the origin of smallpox: correlating variola phylogenies with historical smallpox records,” PNAS, 104:15787-15792 (2007).
[cited by applicant]
Lohr et al., “New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation,” Vaccine, 27(36):4975-4982 (2009).
[cited by applicant]
Loy, “An Account of Some Experiments on the Origin of the Cow-Pox,” Webster (1801) (29 Pages).
[cited by applicant]
Mack et al., “A prospective study of serum antibody and protection against smallpox,” The American Journal of Tropical Medicine and Hygiene, 21: 214-218 (1972).
[cited by applicant]
Marriott et al., “Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge,” Vaccine, 26: 581-588 (2008).
[cited by applicant]
Medaglia et al., “Genomic analysis, phenotype, and virulence of the historical Brazilian smallpox vaccine strain IOC: Implications for the origins and evolutionary relationships of vaccinia virus,” Journal of Virology, …
[cited by applicant]
Merkel et al., “Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities,” PNAS, 107:18091-18096 (2010).
[cited by applicant]
Monath et al., “ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)—a second-generation smallpox vaccine for biological defense,” International Journal of Infectious Diseases, 8(Supp …
[cited by applicant]
Morikawa et al., “An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection,” Journal of Virology, 79:11873-11891 (2005).
[cited by applicant]
Murphy et al., “Adventitious Agents and Smallpox Vaccine in Strategic National Stockpile,” Emerging Infectious Diseases, 11(7):1086-1089 (2005).
[cited by applicant]
Nalca et al., “ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile,” Drug Design, Development Therapy, 4:71-79 (2010).
[cited by applicant]
Noyce et al., “Construction of an infectious horsepox virus vaccine from chemically synthesized DNA Fragments,” PLOS One, 13(1):e0188453 (2018) (16 pages).
[cited by applicant]
Noyce et al., “Synthetic horsepox viruses and the continuing debate about dual use research, ” PLoS Pathogens, 14(10):e1007025 (2018) (5 pages).
[cited by applicant]
Oldfield et al., “Genome-wide engineering of an infectious clone of herpes simplex virus type 1 using synthetic genomics assembly methods,” PNAS, 114(42):e8885-e8894 (2017).
[cited by applicant]
Osborne et al., “Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3,” Vaccine, 25:8807-8832 (2007).
[cited by applicant]
Paez et al., “Stability of vaccinia virus DNA during persistent infections: accumulation of left-end deletions and of tandem repeats at both ends of the viral genome and prevention by interferon,” Virology, 163(1):145-1…
[cited by applicant]
Pallesen et al., “Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen,” PNAS, 114(35):E7348-E7357 (2017).
[cited by applicant]
Park et al., “Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer,” Molecular Therapy, 23(9):1532-2540 (2015).
[cited by applicant]
Qin et al., “Evolution of and evolutionary relationships between extant vaccinia virus strains,” Journal of Virology, 89(3):1809-1824 (2015).
[cited by applicant]
Qin et al., “Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine,” Journal of Virology, 85(24):13049-13060 (2011).
[cited by applicant]
Ralph et al., “2019-nCOV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness,” Journal of Infection in Developing Countries, 31:14(1):3-17 (2020).
[cited by applicant]
Rice et al., “An efficient method for generating poxvirus recombinants in the absence of selection,” Viruses, 3(3): 217-232 (2011).
[cited by applicant]
Roberts et al., “A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice, ” PLoS Pathogens, 3(1):e5.doi: 10.1371 (2007).
[cited by applicant]
Sadoff et al., “Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineInterim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine,” New England Journal of Medicine, 384(19):1824-1835 (2021).
[cited by applicant]
Sam et al., “Expression of poxvirus DNA in coinfected cells and marker rescue of thermosensitive mutants by subgenomic fragments of DNA,” Annales de Institut Paseur/Virologie, 132(2):135-150 (1981).
[cited by applicant]
Sarkar et al., “The minimum protective level of antibodies in smallpox,” Bull World Health Organ, 52:307-311 (1975).
[cited by applicant]
Scheiflinger et al., “Construction of chimeric vaccinia viruses by molecular cloning and packaging, ” PNAS, 89(21):9977-81 (1992).
[cited by applicant]
Schrick et al., An Early American Smallpox Vaccine Based on Horsepox, New England Journal of Medicine, 377(15):1491-1492 (2017).
[cited by applicant]
Shvalov et al., “Complete Genome Sequence of Vaccinia Virus Strain L-IVP,” Genome Announcements, 4(3):e00372-16 (2016).
[cited by applicant]
Subbarao et al., “Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice,” Journal of Virology, 78(7):3572-357…
[cited by applicant]
Tcherepanov et al., “Genome Annotation Transfer Utility (GATU): rapid annotation of viral genomes using a closely related reference genome,” BMC Genomics, 7:150 (2006) (10 pages).
[cited by applicant]
Tonix Pharmaceuticals Press Release “Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus f…
[cited by applicant]
Tulman et al., “Genome of horsepox virus,” Journal of Virology, 80(18):9244-9258 (2006).
[cited by applicant]
Vivalis, “From cells to therapeutics, Forget eggs and accelerate your vaccine development with the EBx®cell line,” (4 pages) (undated).
[cited by applicant]
Walsh et al., “Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors,” Expert Review of Vaccines, 10:1221-1240 (2011).
[cited by applicant]
Weltzin et al., “Clonal vaccinia virus grown in cell culture as a new smallpox vaccine,” Nature Medicine, 9(9):1125-1130 (2003).
[cited by applicant]
WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting, Nov. 2-3, 2016, Geneva, Switzerland, World Health Organisation, ww.who.int/csr/resources/publications/smallpox/variola-research-novembe…
[cited by applicant]
Yager et al., “Pathology of Domestic Animals,” The skin and appendages, K. V. F. Jubb, p. C. Kennedy, N. Palmer, 4th Edition, vol. 1., Academic Press, San Diego, CA, pp. 531-738 (1993) (787 pages) (4 parts).
[cited by applicant]
Yao et al., “Construction of recombinant vaccinia viruses using leporipoxvirus—catalyzed recombination and reactivation of orthopoxvirus DNA,” Methods in Molecular Biology, 269:51-64 (2004).
[cited by applicant]
Yao et al., “High-frequency genetic recombination and reactivation of orthopoxviruses from DNA fragments transfected into leporipoxvirus-infected cells,” Journal of Virology, 77(13):7281-7290 (2003).
[cited by applicant]
Zhang et al., “Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus,” Cancer Research, 67(20):10038-46 (2007).
[cited by applicant]
Domi et al., “Engineering of a vaccinia virus bacterial artificial chromosome in
[cited by applicant]
Antoine et al., “The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses,” Virology, 244(2):365-396 (1998).
[cited by applicant]
Chan et al., “Oncolytic Poxviruses,” Annual Review of Virology, 1:191-214 (2014).
[cited by applicant]
Becker et al., “Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice,” PNAS, 105(50):19944-9 (2008).
[cited by applicant]
Cello et al., “Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template,” Science, 297:1016-1018 (2002).
[cited by applicant]
Tumpey et al., “Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus,” Science, 310:77-80 (2005).
[cited by applicant]
Wimmer et al., “Synthetic viruses: a new opportunity to understand and prevent viral disease,” Nature Biotechnology, 27(12):1163-72 (2009).
[cited by applicant]
Kettle et al., “Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode Mr 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model,” Virology, 206:136-147 (1995).
[cited by applicant]